8-K: Phio Pharmaceuticals Secures $621,000 Investment from Triton Funds

Phio Pharmaceuticals has entered into a purchase agreement with Triton Funds for up to $621,000 through the sale of common stock.

Summary

• Phio Pharmaceuticals has entered into a purchase agreement with Triton Funds LP, where Triton will purchase up to 862,500 shares of Phio's common stock.
• The purchase price is set at $0.72 per share, potentially yielding gross proceeds of up to $621,000 for Phio.
• The agreement is valid until the earlier of all shares being purchased or November 17, 2024.
• Triton's ownership is capped at 19.99% of Phio's outstanding common stock.
• Triton has the option to reduce the number of shares purchased if Phio's stock price falls below $0.72 before the closing date.
• Phio will file a prospectus supplement related to this offering.
• Triton is obligated to purchase shares when directed by Phio, subject to the terms of the agreement.
• Triton is prohibited from short selling Phio's stock during the agreement period.

Sentiment

Score: 7

Explanation: The document indicates a positive development for Phio Pharmaceuticals, securing funding for its operations. However, the potential for dilution and the investor's option to reduce purchases temper the overall sentiment.

Positives

• Phio Pharmaceuticals gains access to up to $621,000 in funding.
• The agreement provides a structured way for Phio to raise capital.
• Triton Funds is a specialist investor in microcap equities, which may bring additional expertise and support.
• The investment validates Phio's INTASYL technology.

Negatives

• The agreement is capped at 862,500 shares, limiting the potential capital raise.
• Triton has the option to reduce the number of shares purchased if the stock price falls below $0.72, which could reduce the total capital raised.
• The agreement may lead to dilution of existing shareholders' equity.

Risks

• The actual amount of capital raised depends on Phio's decisions and market conditions.
• The stock price could fall below $0.72, potentially reducing the total investment.
• The agreement could lead to dilution of existing shareholders' equity.
• There is no guarantee that all 862,500 shares will be purchased by Triton.
• The company is reliant on the registration statement remaining effective.

Future Outlook

Phio Pharmaceuticals intends to use the funds raised from this agreement to support its operations and development of its INTASYL technology. The company will continue to monitor market conditions and make decisions regarding the timing and amount of share sales to Triton.

Management Comments

• Robert Bitterman, Phio President and CEO, stated that they are pleased to have TRITON Funds take a significant position in their Company.
• Robert Bitterman believes that the investment further establishes recognition for their INTASYL program as a unique alternative for treatment of solid tumors.
• Axel Olson, investment representative at TRITON Funds, remarked that their investment in Phio Pharmaceuticals, with its INTASYL technology, embodies their philosophy of combining intelligent scientific innovation with exceptional management.

Industry Context

This agreement reflects a trend of microcap biotech companies seeking alternative financing methods. The investment from Triton Funds, which specializes in microcap equities, indicates a belief in Phio's technology and potential for growth in the immuno-oncology space.

Comparison to Industry Standards

• The agreement is a common form of financing for small biotech companies, often used to fund ongoing research and development.
• The use of a shelf registration statement is a standard practice for companies that may need to raise capital quickly.
• The 19.99% ownership cap is a common provision to avoid triggering certain regulatory requirements.
• The ability for the investor to reduce the number of shares purchased if the stock price falls is a standard protection for the investor.

Stakeholder Impact

• Shareholders may experience dilution of their equity.
• The company gains access to capital to fund operations and research.
• Employees may benefit from the company's improved financial position.
• Customers may benefit from the continued development of Phio's technology.

Next Steps

• Phio Pharmaceuticals will file a prospectus supplement with the SEC.
• Phio Pharmaceuticals will decide when and how many shares to sell to Triton Funds.
• Triton Funds will purchase shares as directed by Phio, subject to the terms of the agreement.

Key Dates

Keywords

capital raise, common stock, purchase agreement, Triton Funds, equity financing, INTASYL, microcap, biotechnology, share issuance